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SUPPLEMENTARY NOTES
ABSTRACT
The TMPRSS2/ERG fusion gene is detected in about 50% of prostate cancer (PCa) patients. It is highly specific for PCa and involved in proliferation and invasion of PCa cells. Some prostate cancers express a single mRNA type, while others express multiple isoforms of the fusion gene that arise via alternative splicing of the initial fusion transcript. The goal of the project is to target the four most common and biologically active alternatively spliced fusion gene transcript isoforms using specifcaly designed siRNAs to obtain maximal biological activity in cancers expressing the particular isoform or a combination of isoforms. Although siRNA offers a powerful tool to silence gene expression of drugable and undrugable targets, in vivo delivery of siRNA remains a great challenge. Therefore development of tumor-specific safe and effective nanodelivery systems is the main goal of the studies for clinical applications of siRNA-therapeutics. We propose to use nanoliposomes encapsulating siRNAs specifically targeting the TMPRSS2/ERG mRNA fusion junctions, to minimize off-target effects in normal tissues so toxicity should be minimal. Our results support the efficacy of this approach.
SUBJECT TERMS
None provided. Since its discovery, use of small-interfering RNA (siRNA) has rapidly become a pow erful tool to silence gene expression and has a g reat potential for use of molecularly targeted therapies in cancer. siRNA specifically binds target mRNA and causes its degradation, inhibiting protein expression. The promise of sequence-specific target degradation has also generated much excitement for silencing of not only drugable also "nondrugable" targets that cannot be targeted by small inhibitors. However, currently in vivo delivery of siRNA-based therapeutics to primary tumor and its metastases remains a g reat challenge. Clinical trials with siRNA was successful when administered locally. While negatively charged cell membranes prevent efficient intracellular delivery of nucleotides, cationic liposomes exhibit toxicity to mammalian cells. Therefore development of tumor-specific safe and effective nanodelivery systems is the main goal of the studies for clinical applications of siRNA-therapeutics. We recently developed non-toxic neutrally charged 1,2-dioleoylsn-glycero-3-phosphatidylcholine (DOPC)-based lipsosomal nanovectors (mean size 65nm) that can target siRNA in vivo into tumor cells 10-fold and 3 0-fold more effectively than cationic lipids and naked siRNA, respectively, leading to significant and robust target gene silencing in orthotopic cancer models.
The TMPRSS2/ERG fusion gene is absolutely specific for prostate cancer cells, since the fusion transcript is only present in these cells. Unfortunately, there is heterogeneity in the structure of the 5' end of the mRNA transcripts of the fusion gene as described above. Thus, some prostate cancers express a single mRNA type, while others express multiple isoforms of the fusion gene that arise via alternative splicing of the initial fusion transcript. We seek to target the four most common and biologically active alternatively spliced fusion gene transcript isoforms, which constitute greater than 95% of all transcripts, to obtain maximal biological activity in cancers expressing a specific isoform or a combination of isoforms. In vivo knockdown of TMPRSS2/ERG fusion gene expression using liposomal nanovectors should decrease prostate cancer progression in vivo and be an effective therapeutic strategy in human prostate cancers bearing this fusion gene. Given the extremely high prevalence of this chromosomal alteration in human prostate cancer, the majority of prostate cancers may be a menable to this treatment. In this proposal we use siRNAs specifically targeting the TMPRSS2/ERG mRNA fusion junctions, which are present only in PCa cells, to minimize off-target effects in normal tissues so toxicity is minimal while gene knockdown results in significant inhibition of tumors growth. Figure 2 . One week after orthotopic injection mice with luciferase-expressing VCaP cells, treatment was initiated with SiRNAs delivered using DOPC liposomes. Mice were injected with control or twice weekly. Mouse weight was followed and tumor imaging was performed weekly using a Xenogen imaging system after luciferin injection. The experiment was terminated after 4 weeks of treatment and primary tumors weighed and submitted for histopathology and complete necropsy performed on mice. Mice were euthanized 48 hours following the last injection of SiRNA. Of note, no toxicity was noted in any mouse. Tumor weights are shown in Quantitative analysis of Western blots revealed a strong correlation between tumor levels of ERG and final tumor weight (r(2)=.64, p=.007; Fig 4B) . These results indicate that variable delivery or efficacy of siRNA due to tumor or mouse specific factors is decreasing the therapeutic efficacy of the siRNA treatments. To determine the mechanism(s) of decreased tumor growth in SiRNA treated tumors we quantitated proliferation using Ki67 immunohistochemistry (IHC) and image analysis of stained sections. As shown in Fig 5A, proliferation was significantly decreased in treated tumors (p<.001, Mann Whitney). A similar analysis of angiogenesis was carried using IHC with anti-CD31 antibody (Fig 5B) . The extent of blood vessels in Si8 and Si14 treated tumors was significantly decreased (p<.001) relative to scrambled control treated tumors (SCN).
BODY
TUNEL analysis showed a significant increase in apoptotic cells in treated tumors from 1.8% (scrambled control to 2.0 (Si8, p=.03) or 3.4% (Si14, p=.008). All of these effects are consistent with the decreased tumor growth observed. The effect on angiogenesis is unexpected since the T/E fusion gene has not been previously linked to promotion of angiogenesis. Further mechanistic studies are needed to discern the mechanism for this decrease in angiogenesis.
While we have shown significant anti-tumor effects of our T/E fusion gene targeting nanoliposomal vectors we need to further enhance delivery in order to maximize therapeutic efficacy. Although liposomes have demonstrated one of the best established nanoplatforms with several-FDA approved formulations for cancer treatment, unmodified liposomes are limited by their short blood circulation time due to elimination by reticuloendothelial system. To increase stability and blood circulation halflife coating nanoparticles with polymers such as polyethlyglycol (PEGylation) To increase tissue specific delivery we also tested target g ene silencing single injection of nanolipsomal siRNA (4ug/mouse) with variety of liposomes decorated with folate or RGD (PEG2000-folate or PEG2000-RGD0. As shown in Figure 6B when compared with the inhibition of expression with those induced by DOPC-siRNA PEG liposomes which led to target gene expression for 6 days(2 mice /group) we did not see additional increase by folate or RDG coated liposomes.. B. Single injection of nanolipsomal siRNA (4ug/mouse) with variety of liposomes decorated with PEG2000 or PEG2000-folate or PEG2000-RGD leads to target gene expression for 6 days(2 mice /group).
Goal 2: Evaluation of the efficacy of the SiRNA knockdown of the Type VI fusion gene in vivo
Results:
We designed as series of 18 siRNAs spanning the fusion junction of the TMPRSS2 and ERG genes in the Type VI fusion mRNA. We then tested these SiRNAs systematically using transient transfection in 293T, PNT1a expressing the Type VI fusion using Western blot and/or quantitative RT-PCR. Of the 18 original SiRNAs we identified four that gave strong, consistent and reproducible knockdown of the Type VI TMPRSS2/ERG fusion gene. Figure 7 shows a Western blot of with anti-V5 antibody on cell extracts of 293T cells transiently transfected with V5-Tagged Type VI fusion gene and several SiRNAs. Control cells are liposomes only while scrambled represents a non-specific SiRNA. As can be seen in Figure 7 , Si1, Si8, Si14 and Si15 all give very strong knockdown of the fusion gene. These results were confirmed by quantitative RT-PCR in 293T and PNT1a with Type VI fusion. In several experiments Si14 gave the best consistent knockdown.
We then evaluated the specificity of the siRNAs targeting the Type III and Type VI fusion genes. 293T cells were transfected with plasmids encoding Type III or Type VI fusion gene and siRNAs specifically targeting the Type III or Type VI junctions. It should be noted that the two plasmids differ by only 5 amino acids in their encoded proteins and contain almost the entire ERG protein. We showed (Dr. Ittmann) the specific siRNAs for each isoform show strong knockdown of their specific targeted isoform without any effect on the other isoform.
We then established Type VI expressing VCaP cells using a lentivirus. Nude mice were injected subcutaneously with VCaP vector control cells or VCaP expressing the Type VI fusion gene (VCaP TE6). After two weeks we then treated mice with siRNA targeting the Type VI fusion gene (Si14, Fig  7) or scrambled control siRNA for 4 weeks. Not surprisingly, as shown in Fig 9, the VCaP cells expressing the Type VI fusion grew significantly faster than VCaP controls when treated with scrambled control RNA (p=.04). However, when Type VI expressing VCaP were treated with siRNA targeting the Type VI fusion they were significantly growth inhibited compared to the same cells treated with scrambled control (p=.035) and had similar tumor weights to VCaP control cells indicating that the growth promoting activity of the Type VI fusion was completely abrogated by the specific siRNA targeting this isoform. We designed as series of 18 siRNAs spanning the fusion junction of the TMPRSS2 and ERG genes in the Type I and Type II fusion mRNAs. We then tested these SiRNAs systematically using transient We have established Type I and Type II fusion gene expressing VCaP cells using a lentivirus and these cells are ready for in vivo experiments. We plan to carry out these experiments this summer using unrestricted funds available to us. Summary We have developed highly effective siRNAs targeting all the most common TMPRSS2/ERG fusion gene isoforms. Furthermore, we have shown efficacy in vivo with long-acting Peglated nanoliposomes containing siRNAs in an or thotopic and subcutaneous models with no toxicity. However, to improve efficacy we have had to further optimize the DOPC liposome by PEGylation, which appears to significantly enhance gene knockdown.
KEY RESEARCH ACCOMPLISHMENTS
• Developed high efficiency siRNAs targeting the Type III fusion gene mRNA.
• Developed high efficiency siRNAs targeting the Type VI fusion gene mRNA.
• Developed high efficiency siRNAs targeting the Type I and II fusion gene mRNAs.
• Showed efficacy and lack of toxicity in vivo of siRNAs delivered via DOPC liposomes using orthotopic and subcutaneous VCaP models.
• Developed long-acting PEGylated nanoliposomes containing siRNAs for longer target gene downregulation in invivo Pca tumor models • Developed VCaP cells expressing Type I, II and V I fusion gene mRNAs for evaluation of DOPC liposomes with siRNAs targeting these variants in vivo.
REPORTABLE OUTCOMES
• Identification of junction specific siRNAs targeting all the most common isoforms of the TMPRSS2/ERG fusion gene • Using DOPC liposomes to deliver specific siRNAs targeting the Type III and VI fusion gene isoforms we have demonstrated statistically significant downregulation of tumor progression in vivo.
• We have shown that PEGylated DOPC liposomes are more effective than unmodified
